Vinconate is an indolonaphthyridine derivative and can stimulate the muscarinic acetylcholine receptor.

In dialysate dopamine concentrations significantly increased by Vinconate (50 to 200 mg/kg p.o.). Daily treatment with Vinconate (25 mg/kg) for 7 days also significantly increases dopamine and serotonin concentrations in dialysate[1]. In [3H]QNB binding in the nucleus accumbens and cerebellum, Chronic treatment with Vinconate at a 10 mg/kg significantly ameliorats the reduction . Furthermore, this Vinconate treatment significantly enhances [3H]QNB binding in the frontal cortex and hippocampus compare with the vehicle-treated aged animals. Also, chronic treatment with Vinconate at the higher dose significantly elevates [3H]QNB binding in the hippocampal CA3 sector and dentate gyrus compare with the vehicle-treated aged animals. Chronic treatment with Vinconate at a dose of 10 mg/kg shows a significant reduction in [3H]HC binding only in the hippocampal CA1 sector compare with the vehicle-treated aged rats[2].